Navigation Links
Eisai Joins Groundbreaking Tuberculosis Drug Accelerator Partnership to Discover New Tuberculosis Drugs

TOKYO, Nov. 25, 2013 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has become a signatory to the Tuberculosis Drug Accelerator (TBDA) partnership, a groundbreaking initiative that aims to speed up the discovery of essential new treatments for tuberculosis (TB).

(Logo: )

Jointly launched in June 2012 through a collaborative agreement among seven pharmaceutical companies1 and six research institutions2 with support from the Bill & Melinda Gates Foundation, the TBDA partnership targets the discovery of new TB drugs by working together on early-stage research. The long-term goal of the partnership is to create a new TB drug combination that has the potential to cure patients in only one month, compared to the six months of treatment required by existing drugs. Based on the partnership, the participating pharmaceutical companies will open up targeted sections of their compound libraries and share data with other participating pharmaceutical companies and research institutions. As a TBDA member, Eisai will provide selected portions of its chemical library for screening against TB as well as share identified and confirmed hits with other TBDA partners. Eisai will also work cooperatively with other partners to facilitate the development of new therapies for TB.

TB is a contagious disease caused by a bacterial infection that affects the lungs and other organs.  Although it is a curable and preventable disease, it is the second leading infectious cause of death worldwide, having resulted in the deaths of 1.4 million people in 2011 alone. One of the main reasons for the high mortality is that first-line therapies for TB are antiquated and inadequate, with all existing drugs being at least 50 years old and requiring at least six months to cure the disease. Furthermore, the length of the existing TB treatments means that a considerable number of patients drop out before completion, which in turn can lead to further transmission, emergence of drug resistance, and death. By discovering a new TB drug combination with the potential to cure patients in one month, the TBDA will contribute to shortening the length of treatment as well as decreasing treatment default rates.

Eisai is committed to improving the health and welfare of people in developing and emerging countries and considers its contributions to the economic development and expansion of the middle-income class through these endeavors as a form of long-term investment for future market growth. To achieve this, Eisai remains actively committed to addressing issues in global health to further increase the benefits provided to patients and their families worldwide.

1 AbbVie, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck, Sanofi

2 Infectious Disease Research Institute, National Institute of Allergy and Infectious Diseases, Rutgers University, Texas A&M University, University of Dundee, Weill Cornell Medical College

Media Inquiries:  
Public Relations Department,  
Eisai Co., Ltd.  



SOURCE Eisai Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
2. Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
3. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
4. Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey Relief Fund, $50,000 to the American Red Cross
5. Eisai Oncology to Present New Research on Eribulin at 35th Annual San Antonio Breast Cancer Symposium
6. FDA Grants Orphan Drug Status To Eisais Lenvatinib
7. Lynn Kramer, MD, Appointed Chief Clinical Officer of Eisai Product Creation Systems
8. Eisai To Sponsor 7th Annual National Walk For Epilepsy To Help Raise Epilepsy Awareness
9. Eisai USA Foundation to Donate $1 Million to the Conquer Cancer Foundation of the American Society of Clinical Oncology
10. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
11. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Post Your Comments:
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
Breaking Medicine News(10 mins):